Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen

Status

Treatments: Drug: Tucatinib

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03424473

ONT-380-014

Details and patient eligibility

About

Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information ([e-mail]).

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria